126 related articles for article (PubMed ID: 16684076)
1. The CARI guidelines. Biochemical targets.
Hawley C; Elder G;
Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S198-216. PubMed ID: 16684076
[No Abstract] [Full Text] [Related]
2. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone.
Elder G; Faull R; Branley P; Hawley C;
Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S230-61. PubMed ID: 16684078
[No Abstract] [Full Text] [Related]
3. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy.
Goldsmith RS; Johnson WJ
Kidney Int; 1973 Aug; 4(2):154-60. PubMed ID: 4744973
[No Abstract] [Full Text] [Related]
4. [Renal osteodystrophy].
Schober HC
Z Urol Nephrol; 1986 Oct; 79(10):595-602. PubMed ID: 3811647
[No Abstract] [Full Text] [Related]
5. Progress of renal osteodystrophy during continuous ambulatory peritoneal dialysis.
Buccianti G; Bianchi ML; Valenti G
Clin Nephrol; 1984 Dec; 22(6):279-83. PubMed ID: 6525771
[TBL] [Abstract][Full Text] [Related]
6. [Studies on abnormalities of calcium, vitamin D and bone metabolism in patients on maintenance hemodialysis (author's transl)].
Kitoh C
Nihon Jinzo Gakkai Shi; 1979 May; 21(5):503-18. PubMed ID: 529620
[No Abstract] [Full Text] [Related]
7. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.
Gardham C; Stevens PE; Delaney MP; LeRoux M; Coleman A; Lamb EJ
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1261-7. PubMed ID: 20498246
[TBL] [Abstract][Full Text] [Related]
8. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
[TBL] [Abstract][Full Text] [Related]
9. Treatment of renal osteodystrophy in advanced renal failure during predialysis time.
Fröhling PT; Kokot F; Vetter K; Hohmann WD; Werner G; Grossmann I; Schmicker R; Lindenau K
Contrib Nephrol; 1984; 37():62-5. PubMed ID: 6609046
[No Abstract] [Full Text] [Related]
10. [Management of renal osteopathy in patients with chronic dialysis].
Kiss D; Brunner FP
Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
[TBL] [Abstract][Full Text] [Related]
11. Effects of dialysis prescription on bone and mineral metabolism: the National Cooperative Dialysis Study.
Harter HR; Laird NM; Teehan BP
Kidney Int Suppl; 1983 Apr; (13):S73-9. PubMed ID: 6345900
[No Abstract] [Full Text] [Related]
12. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)].
Pogglitsch H; Schmidberger H; Gell G
MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443
[TBL] [Abstract][Full Text] [Related]
13. Clinical problems of renal osteopathy in patients on hemofiltration.
Schulz W; Baier E; Hümpfner A; Delling G
Contrib Nephrol; 1982; 32():86-91. PubMed ID: 7128166
[No Abstract] [Full Text] [Related]
14. Growth hormone and renal osteodystrophy: a case report.
Kaufman DB
Pediatr Nephrol; 1998 Feb; 12(2):157-9. PubMed ID: 9543380
[TBL] [Abstract][Full Text] [Related]
15. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
[TBL] [Abstract][Full Text] [Related]
16. Do differences in dialysis prescription impact on KDOQI bone mineral targets? The Pan Thames Renal Audit.
Davenport A; Gardner C; Delaney M;
Blood Purif; 2010; 30(2):111-7. PubMed ID: 20714141
[TBL] [Abstract][Full Text] [Related]
17. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
18. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
19. Effect of CKD-MBD phenotype on health-related quality of life in patients receiving maintenance hemodialysis: A cross-sectional study.
Luo L; Chen Q
J Int Med Res; 2020 Feb; 48(2):300060519895844. PubMed ID: 32054360
[TBL] [Abstract][Full Text] [Related]
20. Bone disease in renal failure. Clinical and histomorphometric studies.
Nilsson P
Scand J Urol Nephrol Suppl; 1984; 84():1-68. PubMed ID: 6393322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
